Feb 15 |
NanoViricides GAAP EPS of -$0.18
|
Feb 15 |
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
|
Feb 1 |
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
|
Jan 29 |
NanoViricides reports positive safety results for COVID drug candidate
|
Jan 29 |
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
|
Jan 4 |
NanoViricides to Present at the Biotech Showcase in San Fransisco
|
Nov 29 |
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387
|
Nov 28 |
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
|
Nov 15 |
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
|
Nov 14 |
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
|